Literature DB >> 11799153

Properties of the surface envelope glycoprotein associated with virulence of simian-human immunodeficiency virus SHIV(SF33A) molecular clones.

Lisa A Chakrabarti1, Tijana Ivanovic, Cecilia Cheng-Mayer.   

Abstract

In vivo adaptation of simian-human immunodeficiency virus (SHIV) clone SHIV(SF33) resulted in the emergence of pathogenic isolate SHIV(SF33A), which caused a rapid and severe CD4(+) T-cell depletion when inoculated into rhesus macaques. Two molecular clones generated by inserting the env V1-to-V5 region amplified from SHIV(SF33A)-infected animals into the parental SHIV(SF33) genome retained a pathogenic phenotype. The gp120 envelope glycoproteins of pathogenic clones SHIV(SF33A2) and SHIV(SF33A5) conferred a threefold increase in viral entry and fusogenicity compared to the parental glycoprotein. Changes in gp120 were also responsible for a higher replication capacity and cytopathicity in primary CD4(+) T-cell cultures. Last, gp120 carried the determinants of SHIV(SF33A) neutralization resistance. Thus, changes in SHIV(SF33A) gp120 produced a set of properties that could account for the pathogenic phenotype observed in vivo. Measurement of antibody binding to SHIV(SF33A) viral particles revealed an increased exposure of the CD4-induced epitope recognized by the 17b monoclonal antibody in a region that was shown to contribute to coreceptor binding. Exposure of this epitope occurred in the absence of CD4 binding, suggesting that the envelope glycoprotein of pathogenic SHIV(SF33A) clones folded in a conformation that was primed for interaction with CXCR4 or for the subsequent step of fusion.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11799153      PMCID: PMC135897          DOI: 10.1128/jvi.76.4.1588-1599.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  62 in total

Review 1.  Beyond receptor expression: the influence of receptor conformation, density, and affinity in HIV-1 infection.

Authors:  R W Doms
Journal:  Virology       Date:  2000-10-25       Impact factor: 3.616

2.  Association of structural changes in the V2 and V3 loops of the gp120 envelope glycoprotein with acquisition of neutralization resistance in a simian-human immunodeficiency virus passaged in vivo.

Authors:  Y Ye; Z H Si; J P Moore; J Sodroski
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Generation of a chimeric human and simian immunodeficiency virus infectious to monkey peripheral blood mononuclear cells.

Authors:  R Shibata; M Kawamura; H Sakai; M Hayami; A Ishimoto; A Adachi
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

4.  Infection of cynomolgus monkeys with a chimeric HIV-1/SIVmac virus that expresses the HIV-1 envelope glycoproteins.

Authors:  J Li; C I Lord; W Haseltine; N L Letvin; J Sodroski
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1992

5.  Virions of primary human immunodeficiency virus type 1 isolates resistant to soluble CD4 (sCD4) neutralization differ in sCD4 binding and glycoprotein gp120 retention from sCD4-sensitive isolates.

Authors:  J P Moore; J A McKeating; Y X Huang; A Ashkenazi; D D Ho
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

6.  Fusion mutants of the influenza virus hemagglutinin glycoprotein.

Authors:  R S Daniels; J C Downie; A J Hay; M Knossow; J J Skehel; M L Wang; D C Wiley
Journal:  Cell       Date:  1985-02       Impact factor: 41.582

7.  Importance of membrane fusion mediated by human immunodeficiency virus envelope glycoproteins for lysis of primary CD4-positive T cells.

Authors:  J A LaBonte; T Patel; W Hofmann; J Sodroski
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

8.  The N-terminal V3 loop glycan modulates the interaction of clade A and B human immunodeficiency virus type 1 envelopes with CD4 and chemokine receptors.

Authors:  S E Malenbaum; D Yang; L Cavacini; M Posner; J Robinson; C Cheng-Mayer
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

Review 9.  Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin.

Authors:  J J Skehel; D C Wiley
Journal:  Annu Rev Biochem       Date:  2000       Impact factor: 23.643

10.  Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.

Authors:  M Thali; J P Moore; C Furman; M Charles; D D Ho; J Robinson; J Sodroski
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

View more
  13 in total

1.  Increased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIV(SF162P3) maps to envelope gp120.

Authors:  Mayla Hsu; Janet M Harouse; Agegnehu Gettie; Clarisa Buckner; James Blanchard; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

2.  Addition of a single gp120 glycan confers increased binding to dendritic cell-specific ICAM-3-grabbing nonintegrin and neutralization escape to human immunodeficiency virus type 1.

Authors:  James Lue; Mayla Hsu; David Yang; Preston Marx; Zhiwei Chen; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

3.  Thymic pathogenicity of an HIV-1 envelope is associated with increased CXCR4 binding efficiency and V5-gp41-dependent activity, but not V1/V2-associated CD4 binding efficiency and viral entry.

Authors:  Eric G Meissner; Vernon M Coffield; Lishan Su
Journal:  Virology       Date:  2005-06-05       Impact factor: 3.616

4.  HIV Vpu Interferes with NF-κB Activity but Not with Interferon Regulatory Factor 3.

Authors:  Lara Manganaro; Elisa de Castro; Ana M Maestre; Kevin Olivieri; Adolfo García-Sastre; Ana Fernandez-Sesma; Viviana Simon
Journal:  J Virol       Date:  2015-07-15       Impact factor: 5.103

5.  IL-15 regulates susceptibility of CD4+ T cells to HIV infection.

Authors:  Lara Manganaro; Patrick Hong; Matthew M Hernandez; Dionne Argyle; Lubbertus C F Mulder; Uma Potla; Felipe Diaz-Griffero; Benhur Lee; Ana Fernandez-Sesma; Viviana Simon
Journal:  Proc Natl Acad Sci U S A       Date:  2018-09-26       Impact factor: 11.205

6.  Recombinant extracellular domains of tetraspanin proteins are potent inhibitors of the infection of macrophages by human immunodeficiency virus type 1.

Authors:  Siu-Hong Ho; Francine Martin; Adrian Higginbottom; Lynda J Partridge; Varadarajan Parthasarathy; Gregory W Moseley; Peter Lopez; Cecilia Cheng-Mayer; Peter N Monk
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

7.  Targeting Viral Proteostasis Limits Influenza Virus, HIV, and Dengue Virus Infection.

Authors:  Nicholas S Heaton; Natasha Moshkina; Romain Fenouil; Thomas J Gardner; Sebastian Aguirre; Priya S Shah; Nan Zhao; Lara Manganaro; Judd F Hultquist; Justine Noel; David Sachs; Jennifer Hamilton; Paul E Leon; Amit Chawdury; Shashank Tripathi; Camilla Melegari; Laura Campisi; Rong Hai; Giorgi Metreveli; Andrea V Gamarnik; Adolfo García-Sastre; Benjamin Greenbaum; Viviana Simon; Ana Fernandez-Sesma; Nevan J Krogan; Lubbertus C F Mulder; Harm van Bakel; Domenico Tortorella; Jack Taunton; Peter Palese; Ivan Marazzi
Journal:  Immunity       Date:  2016-01-19       Impact factor: 31.745

8.  V3 loop-determined coreceptor preference dictates the dynamics of CD4+-T-cell loss in simian-human immunodeficiency virus-infected macaques.

Authors:  Siu-hong Ho; Lili Shek; Agegnehu Gettie; James Blanchard; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

9.  N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies.

Authors:  Ruth A McCaffrey; Cheryl Saunders; Mike Hensel; Leonidas Stamatatos
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

10.  Influence of long terminal repeat and env on the virulence phenotype of equine infectious anemia virus.

Authors:  Susan L Payne; Xiao-fang Pei; Bin Jia; Angela Fagerness; Frederick J Fuller
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.